V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214251 | 20129771 | 1.72 | 66.5 | Palliative (P) | 2019-02-24 | 2019-03-16 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 101496212 |
| 20214253 | 20129772 | 1.78 | 73 | Palliative (P) | 2016-11-20 | 2017-10-14 | EOX | 02 | N | OXALIPLATIN + RALTITREXED | 101184334 |
| 20214254 | 20129773 | 1.6 | 96 | null | 2019-09-26 | 2019-12-04 | Oxaliplatin + Raltitrexed | 02 | null | OXALIPLATIN + RALTITREXED | 100566402 |
| 20214255 | 20129774 | 1.54 | 74.2 | Palliative (P) | 2017-03-13 | 2017-03-24 | Sorafenib | 02 | Y | SORAFENIB | 100432662 |
| 20214257 | 20129775 | 1.62 | 51 | 03 | 2019-07-31 | 2019-07-31 | Sorafenib | 02 | N | SORAFENIB | 100400433 |
| 20214260 | 20129776 | 1.72 | 0 | Palliative (P) | 2019-11-16 | 2019-12-02 | CETUXIMAB + OXALIPLATIN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100524747 |
| 20214261 | 20129777 | 1.7 | 65.7 | Palliative (P) | 2016-09-19 | 2016-10-03 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 100647275 |
| 20214262 | 20129778 | 1.67 | 36.9 | null | 2019-12-19 | 2019-12-19 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | null | CETUXIMAB + IRINOTECAN + MDG | 100604332 |
| 20214264 | 20129779 | 1.56 | 86 | null | 2020-06-12 | 2020-06-12 | EOX | 02 | null | EOX | 100963251 |
| 20214265 | 20129780 | 1.73 | 60 | Palliative (P) | 2019-09-09 | 2019-09-11 | CETUXIMAB + IRINOTECAN + MDG | N | N | CETUXIMAB + IRINOTECAN + MDG | 100611996 |
| 20214266 | 20129781 | 1.78 | 86 | Adjuvant (A) | 2016-05-27 | 2016-06-04 | Trial Unspecified | 02 | N | TRIAL | 100597620 |
| 20214268 | 20129782 | 1.86 | 50.35 | Neo-adjuvant (N) | 2018-10-10 | 2018-10-10 | EOX | 02 | Y | OXALIPLATIN + RALTITREXED | 101005444 |
| 20214269 | 20129783 | 1.71 | 71 | Palliative (P) | 2016-08-15 | 2016-08-22 | CETUXIMAB + IRINOTECAN + MDG | 99 | N | CETUXIMAB + IRINOTECAN + MDG | 100038495 |
| 20214271 | 20129784 | 1.73 | 66 | Palliative (P) | 2017-08-02 | 2017-08-03 | EOX | 02 | N | OXALIPLATIN + RALTITREXED | 100854519 |
| 20214272 | 20129785 | 1.92 | 101 | Palliative (P) | 2017-08-27 | 2018-04-29 | EOX | 02 | N | OXALIPLATIN + RALTITREXED | 100271370 |
| 20214273 | 20129786 | 1.74 | 85 | Disease modification (D) | 2019-10-24 | 2019-11-03 | EOX | 1 | Y | SORAFENIB | 101018681 |
| 20214274 | 20129787 | 1.44 | 58.8 | Palliative (P) | 2019-12-05 | 2019-12-28 | EOX | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101550365 |
| 20214276 | 20129788 | 1.57 | 88.3 | null | 2020-06-21 | 2020-07-02 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 02 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100885936 |
| 20214277 | 20129789 | 1.56 | 83.58 | Palliative (P) | 2019-03-02 | 2019-04-11 | Trial Unspecified | Y | Y | CETUXIMAB + IRINOTECAN + MDG | 101053354 |
| 20214278 | 20129790 | 1.79 | 43.1 | Palliative (P) | 2018-01-11 | 2019-06-12 | Cetuximab + FLUOROURACIL + OXALIPLATIN | N | N | CETUXIMAB + IRINOTECAN + MDG | 101800908 |
| 20214279 | 20129791 | 1.86 | 75.1 | Palliative (P) | 2019-06-06 | 2019-06-06 | CETUXIMAB + IRINOTECAN + MDG | 2 | N | CETUXIMAB + IRINOTECAN + MDG | 101217445 |
| 20214280 | 20129792 | 1.62 | 78.2 | null | 2016-07-02 | 2016-07-16 | EOX | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101103973 |
| 20214282 | 20129793 | 1.69 | 75.6 | null | 2017-03-25 | 2017-03-25 | Trial Unspecified | 02 | null | TRIAL | 101299740 |
| 20214284 | 20129794 | null | 94.8 | Palliative (P) | 2016-06-19 | 2017-01-02 | Trial Unspecified | N | N | TRIAL | 101471835 |
| 20214287 | 20129795 | 1.63 | 74 | null | 2017-09-26 | 2017-12-31 | EOX | 02 | null | OXALIPLATIN + RALTITREXED | 101290414 |
| 20214288 | 20129796 | 1.7 | 78.2 | Palliative (P) | 2018-10-15 | 2018-10-15 | Sorafenib | 02 | N | SORAFENIB | 101555329 |
| 20214293 | 20129797 | null | null | Neo-adjuvant (N) | 2018-02-10 | 2018-06-13 | EOX | 02 | N | CAPECITABINE + RT | 100326594 |
| 20214296 | 20129798 | 1.63 | 67.1 | Curative (C) | 2018-10-28 | 2020-01-16 | Cetuximab + Oxaliplatin + MdG Maint | 02 | Y | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101207791 |
| 20214297 | 20129799 | 1.61 | 61.6 | Palliative (P) | 2018-04-17 | 2018-05-09 | Sorafenib | 02 | null | SORAFENIB | 100053735 |
| 20214298 | 20129800 | null | null | Neo-adjuvant (N) | 2017-12-05 | 2018-01-09 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 100468568 |
| 20214299 | 20129801 | 0 | 66.7 | Curative (C) | 2020-01-07 | 2020-01-13 | Oxaliplatin + Raltitrexed | 02 | Y | OXALIPLATIN + RALTITREXED | 100995482 |
| 20214300 | 20129802 | 1.6 | 75 | Palliative (P) | 2021-02-14 | 2021-02-28 | Trial Unspecified | 02 | N | EOX | 101477520 |
| 20214301 | 20129803 | 1.79 | 55.8 | Adjuvant (A) | 2020-04-20 | 2020-05-20 | Trial Unspecified | 2 | N | TRIAL | 100449828 |
| 20214302 | 20129804 | null | 63.8 | Palliative (P) | 2018-03-05 | 2018-03-17 | EOX | 99 | N | SORAFENIB | 101047594 |
| 20214304 | 20129805 | 0 | 124 | null | 2016-07-30 | 2016-08-13 | EOX | 02 | null | EOX | 100361010 |
| 20214305 | 20129806 | 1.81 | 83.9 | Palliative (P) | 2016-12-06 | 2016-12-10 | EOX | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100914794 |
| 20214307 | 20129807 | 1.78 | 85.4 | Palliative (P) | 2017-04-06 | 2017-04-06 | EOX | N | N | EOX | 101363006 |
| 20214311 | 20129808 | 1.89 | 46.3 | Palliative (P) | 2017-05-31 | 2019-05-19 | EOX | 02 | N | SORAFENIB | 101167149 |
| 20214312 | 20129809 | 1.7 | 102.7 | Palliative (P) | 2018-01-15 | 2018-01-22 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 100204914 |
| 20214314 | 20129810 | 1.49 | 65 | Palliative (P) | 2019-10-10 | 2019-10-11 | CETUXIMAB + IRINOTECAN + MDG | 02 | Y | CETUXIMAB + IRINOTECAN + MDG | 100678502 |
| 20214315 | 20129811 | 1.57 | 75 | Palliative (P) | 2019-11-18 | 2019-12-09 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | CETUXIMAB + IRINOTECAN + MDG | 101861415 |
| 20214316 | 20129812 | 1.61 | 87 | Palliative (P) | 2019-03-16 | 2019-04-16 | Panitumumab + Irinotecan + MdG | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101304733 |
| 20214318 | 20129813 | 1.75 | 77.6 | Palliative (P) | 2020-04-07 | 2020-04-07 | EOX | 02 | N | TRIAL | 101380634 |
| 20214319 | 20129814 | 1.84 | 58.1 | Palliative (P) | 2019-03-05 | 2019-03-05 | EOX | N | N | EOX | 101152431 |
| 20214325 | 20129815 | 1.83 | 78.2 | Palliative (P) | 2018-06-15 | 2018-06-15 | EOX | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101816293 |
| 20214326 | 20129816 | 1.55 | 56 | Palliative (P) | 2020-03-18 | 2020-04-15 | EOX | 99 | N | CETUXIMAB + IRINOTECAN + MDG | 101082702 |
| 20214327 | 20129817 | null | null | Palliative (P) | 2019-12-30 | 2020-02-14 | Capecitabine 35days + RT | 02 | N | CAPECITABINE + RT | 101542315 |
| 20214328 | 20129818 | 1.78 | 77.1 | Palliative (P) | 2017-11-18 | 2017-12-12 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 02 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100593973 |
| 20214332 | 20129820 | null | 90.4 | Palliative (P) | 2015-07-02 | 2016-10-27 | Cetuximab + FOLFIRI cycle1 | 2 | N | CETUXIMAB + IRINOTECAN + MDG | 100579633 |
| 20214333 | 20129821 | 1.9 | 103 | Adjuvant (A) | 2019-06-23 | 2019-06-23 | EOX | 02 | Y | CAPECITABINE + RT | 101603358 |